{"id":"W4245339559","doi":"10.1200/jco.2014.32.4_suppl.438","title":"EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (aRCC) (ANZUP trial 0901).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Sunitinib; Everolimus; Clinical endpoint; Adverse effect; Internal medicine; Surgery; Renal cell carcinoma; Confidence interval; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001845108,0.0008370832,0.001254396,0.0003174501,0.0003086495,0.000635889,0.0007599927,0.0009390863,0.005143704],"category_scores_gemma":[0.001008129,0.0003803605,0.0008899897,0.0002418488,0.0005346105,0.0008295295,0.0004111624,0.001954716,0.0006579358],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003998633,"about_ca_system_score_gemma":0.001009311,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003971645,"about_ca_topic_score_gemma":0.002083769,"domain_scores_codex":[0.9993874,0.0003911276,0.0000287762,0.00007926519,0.00004119693,0.00007218004],"domain_scores_gemma":[0.9995319,0.00007824336,0.0001280215,0.00003661384,0.00002688608,0.0001984283],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8387173,0.02018146,0.006103566,0.001595399,0.001709495,0.0002066983,0.0002069855,0.001742735,0.01735633,0.0006493148,0.004798831,0.1067318],"study_design_scores_gemma":[0.7887746,0.19391,0.008721185,0.00006910614,0.0007402773,0.0003916884,0.00005287557,0.001094636,0.001854892,0.0003030804,0.004060738,0.00002680125],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9867979,0.004138836,0.0008178753,0.0006325764,0.0002116443,0.003050454,0.001135974,0.000238229,0.002976565],"genre_scores_gemma":[0.9858591,0.001699676,0.003090736,0.001008663,0.000157947,0.003826153,0.00179308,0.00002957509,0.002535061],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005143704,"threshold_uncertainty_score":0.01720738,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1411817375648806,"score_gpt":0.4584591712089288,"score_spread":0.3172774336440483,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}